Sentry LLC’s AbbVie ABBV Stock Holding History

Sentry LLC’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.06M	Hold	8,169	–	–	0.58%	28
2026 Q1	$1.78M	Hold	8,169	–	–	0.57%	25
2025 Q4	$1.87M	Hold	8,169	–	–	0.51%	27
2025 Q3	$1.89M	Hold	8,169	–	–	0.47%	27
2025 Q2	$1.52M	Hold	8,169	–	–	0.3%	29
2025 Q1	$1.71M	Buy	8,169 +23	+0.3%	+$4.47K	0.33%	24
2024 Q4	$1.45M	Hold	8,146	–	–	0.28%	26
2024 Q3	$1.61M	Hold	8,146	–	–	0.31%	25
2024 Q2	$1.4M	Hold	8,146	–	–	0.26%	26
2024 Q1	$1.48M	Sell	8,146 -3	-0%	-$517	0.28%	26
2023 Q4	$1.26M	Buy	8,149 +3	+0%	+$437	0.27%	27
2023 Q3	$1.21M	Hold	8,146	–	–	0.26%	28
2023 Q2	$1.1M	Buy	8,146 +500	+7%	+$73.3K	0.24%	37
2023 Q1	$1.22M	Buy	+7,646	New	+$1.17M	0.29%	30

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Sentry LLC's ABBV Position: Q2 2026 in Review

Sentry LLC held its AbbVie (ABBV) position steady in Q2 2026 at 8,169 shares worth $2.06M. The position accounts for 0.58% of the portfolio, ranked #28.

Sentry LLC first reported a position in ABBV in Q1 2023 and has held it in 14 quarters since. 4,215 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Sentry LLC held 8,169 shares of AbbVie worth $2.06M as of Q2 2026.
Sentry LLC left its AbbVie share count unchanged in Q2 2026.
AbbVie made up 0.58% of Sentry LLC's portfolio in Q2 2026, its #28 holding.
Sentry LLC first reported a position in AbbVie in Q1 2023 and has held it in 14 quarters since.
4,215 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Sentry LLC's 13F filing for Q2 2026, filed 14 Aug 2026.